We came across a bullish thesis on Upstream Bio, Inc. on Value investing subreddit by Dizzy_Drawing_2451. In this article, we will summarize the bulls’ thesis on UPB. Upstream Bio, Inc.'s share was trading at $19.97 as of September 5th.
[caption id="attachment_566773" align="aligncenter" width="750"]Upstream Bios (UPB) is developing Verekitug, a long-acting TSLP receptor-targeted biologic that could reshape treatment in chronic respiratory diseases, including severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and COPD....
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.